J&J Psoriasis Drug Tops Rival Enbrel In Major Study

September 19, 2008

Johnson & Johnson is touting the success of its new psoriasis drug, ustekinumab, also known as Stelara.  The trial revealed that their drug beat out a rival drug from Amgen and Wyeth, Enbrel....Washington (ChattahBox) – Johnson & Johnson is touting the success of its new psoriasis drug, ustekinumab, also known as Stelara.  The trial revealed that their drug beat out a rival drug from Amgen and Wyeth, Enbrel.

The trial, carried out by researchers, compared the new J&J drug to the current leading drug on the market in treating psoriasis, Enbrel.

The Wyeth and Amgen drug Enbrel, at its current level, holds 75% of the global market.

This new study put out though touts some major success for the new drug from Johnson & Johnson.

The Johnson & Johnson drug ustekinumab was successful in reducing severe psoriasis is by 68% in small doses.

It was able to reduce it by 74% in high doses.  This showed it was more effective than Enbrel.

An FDA panel has already unanimously approved the drug, even though that have recomended it only be given by a physician.


Comments

Got something to say? **Please Note** - Comments may be edited for clarity or obscenity, and all comments are published at the discretion of ChattahBox.com - Comments are the opinions of the individuals leaving them, and not of ChattahBox.com or its partners. - Please do not spam or submit comments that use copyright materials, hearsay or are based on reports where the supposed fact or quote is not a matter of public knowledge are also not permitted.